2m 2m 2m 2m 2m 2m 2m
PYXIS ONCOLOGY (PYXS)
NASDAQ
$1.70-$0.005 (-0.29%)
Price as of Jun 03, 2026 4:36 PM EDT- $114.0MMarket Cap
- 29.55%1-Year Change
- BiotechnologyIndustry
PYXIS ONCOLOGY (PYXS)
$1.70-$0.005 (-0.29%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 11.0M -31.64% | 16.1M N/A | N/A N/A | N/A N/A | |
Cost of Revenue | 2.4M +402.74% | 475,000 +137.50% | 200,000 N/A | N/A N/A | |
Gross Profit | 8.7M -44.80% | 15.7M +7,935.50% | -200,000 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -73.7M +25.45% | -58.7M +18.47% | -49.6M -42.43% | -86.1M +68.70% | |
Depreciation and Amortization Expense | 4.5M +51.27% | 3.0M +54.75% | 1.9M +171.79% | 709,000 +9.58% | |
Total Operating Expenses | 22.2M -12.69% | 25.4M -69.07% | 82.2M -33.43% | 123.5M +77.12% | |
Operating Profit | -84.4M -5.63% | -89.5M +8.84% | -82.2M -33.43% | -123.5M +77.12% | |
Interest Income | 650,000 -30.11% | 930,000 -49.51% | 1.8M -33.36% | 2.8M +11,917.39% | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 650,000 -30.11% | 930,000 -49.51% | 1.8M -33.36% | 2.8M +11,917.39% | |
Total Nonoperating Income and Expense | 6.2M -37.93% | 10.0M +18.55% | 8.4M +204.12% | 2.8M +145.86% | |
Income before Taxes | -78.2M -1.59% | -79.5M -3.29% | -82.2M -33.43% | -123.5M +77.12% | |
Income Taxes | 1.4M +164.05% | -2.2M N/A | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -79.6M +2.96% | -77.3M +4.80% | -73.8M -38.87% | -120.7M +58.89% | |
Net Income from Continuing Operations Applicable to Common | -78.2M -1.59% | -79.5M +7.73% | -73.8M -38.87% | -120.7M +58.89% | |
Basic EPS and Net Income | -1.28 -3.03% | -1.32 -28.65% | -1.85 -49.32% | -3.65 -59.22% | |
Diluted EPS and Net Income | -1.28 -3.03% | -1.32 -28.65% | -1.85 -49.32% | -3.65 -59.22% | |
Basic Weighted Average Shares | 62.1M +6.33% | 58.4M +46.46% | 39.9M +20.80% | 33.0M +288.93% | |
Diluted Weighted Average Shares | 62.1M +6.33% | 58.4M +46.46% | 39.9M +20.80% | 33.0M +288.93% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 15.4M -20.80% | 19.5M +101.50% | 9.7M -94.61% | 179.3M -34.74% | |
Short-Term Investments | 51.4M -52.13% | 107.5M -1.98% | 109.6M N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 66.9M -47.33% | 126.9M +6.40% | 119.3M -33.46% | 179.3M -34.74% | |
Total Current Assets | 72.1M -45.56% | 132.4M +6.29% | 124.6M -33.23% | 186.6M -33.04% | |
Accumulated Depreciation | 7.0M +33.90% | 5.2M +45.28% | 3.6M +97.37% | 1.8M +63.53% | |
Property and Plant and Equipment and Net | 8.0M -19.21% | 9.9M -16.62% | 11.9M +6.33% | 11.2M +1,008.74% | |
Total Long-Term Assets | 8.0M -19.21% | 9.9M -16.62% | 11.9M +10,791.74% | 109,000 0.00% | |
Total Assets | 91.5M -41.77% | 157.2M -9.52% | 173.7M -17.81% | 211.4M -24.51% | |
Income Taxes Payable | N/A N/A | 0 -100.00% | 2.2M N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 21.1M +19.52% | 17.7M -31.36% | 25.8M -18.57% | 31.6M +69.09% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 17.0M -9.07% | 18.6M -23.65% | 24.4M +29.10% | 18.9M +11,367.27% | |
Total Liabilities | 38.1M +4.62% | 36.4M -24.14% | 48.0M -5.01% | 50.6M +170.23% | |
Retained Earnings | -443.2M +21.90% | -363.6M +27.02% | -286.2M +34.74% | -212.4M +131.62% | |
Total Stockholders Equity | 53.4M -55.77% | 120.8M -3.94% | 125.7M -21.84% | 160.8M -38.46% | |
Total Shares Outstanding | 62.7M +4.54% | 60.0M +33.99% | 44.8M +28.02% | 35.0M +8.49% | |
Cash Flow | |||||
Cash from Operating Activities | -63.5M +10.11% | -57.7M -18.44% | -70.7M -20.85% | -89.3M +152.89% | |
Capital Expenditures | 9,000 -96.20% | 237,000 -96.48% | 6.7M +5.11% | 6.4M +1,085.00% | |
Cash from Investing Activities | 58.9M +621.73% | 8.2M +107.78% | -104.8M +1,538.52% | -6.4M +984.58% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 594,000 -99.00% | 59.3M +900.61% | 5.9M +3,139.89% | 183,000 -99.94% | |
Financials Ratio | |||||
Gross Margin | 78.37% -19.26% | 97.06% N/A | N/A N/A | N/A N/A | |
Operating Margin | -764.81% +38.04% | -554.07% N/A | N/A N/A | N/A N/A | |
Return on Assets | -64.03% +36.99% | -46.74% +21.96% | -38.32% -22.00% | -49.13% N/A | |
Return on Equity | -91.43% +45.70% | -62.75% +21.84% | -51.51% -9.94% | -57.19% N/A | |
Revenue Growth | -31.64% N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 3.41 -54.45% | 7.49 +54.86% | 4.84 -18.00% | 5.90 N/A | |
Cash Ratio | 0.73 -33.74% | 1.10 +193.55% | 0.38 -93.38% | 5.67 N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow